Recently, the globally renowned biopharmaceutical media Endpoints News conducted an exclusive interview with Dr. Yongliang Fang, Chief Operating Officer of Doer Biologics, and published a report titled "Chinese biotech unveils first-in-class tri-agonist for high lipids, seeks partner". Following is the news link:

https://endpoints.news/zhejiang-doer-biologics-unveils-first-in-class-tri-agonist-for-high-lipids/